Cancer Institute Hospital of JFCR

Koto, Tokyo 135-8550

1 studies enrolling now · 3 studies all time

What they study most

Adjuvant, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, Breast Adenocarcinoma, EGFR, Early Stage Lung Cancer, Endometrial Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Exon 20, Fallopian Tube Cancer, High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer

Studies at this site

• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — Recruiting now
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling